MPM BioImpact

Investing in Healthcare Innovation

[MPM BioImpact @MPMBioImpact]

ICYMI: @orna_tx announced the appointment of Joe Bolen, Ph.D., as CEO! Joe most recently served as Orna’s Chief Scientific Officer and is the ideal leader to advance its potentially best-in-class panCAR programs into the clinic next year. https://t.co/en02to67fH

[MPM BioImpact @MPMBioImpact]

Congrats to @CullinanTx which announced that its Phase 2b trial in patients with NSCLC met its primary endpoint! Cullinan was founded and built by MPM BioImpact and is committed to treating a variety of cancer and autoimmune disorders with high unmet medical needs.

[Cullinan Therapeutics @CullinanTx]

Today, we announced the Phase 2b REZILIENT1 trial of zipalertinib in patients with non-small cell lung cancer (#NSCLC) met its primary endpoint of overall response rate. Zipalertinib is being developed in partnership with Taiho Pharmaceutical and @TaihoOncology. Learn more.

[MPM BioImpact @MPMBioImpact]

Congrats to Dr. Pelka! We are proud to partner with AACR to support high-risk, high-reward research, which may catalyze scientific discoveries and change clinical practice. We look forward to your potential impact on the treatment of mismatch repair-proficient colorectal cancer.

[AACR @AACR]

We congratulate Karin Pelka, PhD, recipient of an AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grant. Dr. Pelka aims to induce anti-tumor immunity hubs in mismatch repair-proficient colorectal cancer, at least in part by using CAR T cells.
@MPMBioImpact

[MPM BioImpact @MPMBioImpact]

Congrats to Dr. Danial! We are excited to partner with AACR to fund paradigm-shifting research, which may advance our understanding of cancer and transform future clinical practice, and we are delighted to support the efforts to impact the treatment of glioma.

[AACR @AACR]

We congratulate Nika Danial, PhD, recipient of an AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grant. Dr. Danial aims to identify lipid-targeted molecular regulators of H3K27M glioma growth by using proteomics and CRISPR-based approaches.
@MPMBioImpact

[MPM BioImpact @MPMBioImpact]

Two portfolio companies built by MPM BioImpact have joined forces: @orna_tx acquires @ReNAgadeTx, uniting the leading circular RNA technology (oRNA®) for in vivo CARs with best-in-class lipid nanoparticle (LNP) delivery solutions for RNA.
Learn more: https://t.co/zeGQv22ZYO

[MPM BioImpact @MPMBioImpact]

Upon joining our portfolio company @orna_tx as CMO later this month, Frank Neumann, MD, PhD, will join MPM BioImpact as an Entrepreneur Partner, working with our diverse team developing therapies for diseases with high unmet needs. https://t.co/ZvhbhjUMkA

[MPM BioImpact @MPMBioImpact]

MPM BioImpact is pleased to participate in the Series A financing of AstronauTx to develop novel treatments for Alzheimer’s disease and other neurodegenerative disorders. Read the press release: https://t.co/4VPUI7T5WJ

[MPM BioImpact @MPMBioImpact]

Excited to be a part of the #DekaBiosciences story! Read the press release here:
https://t.co/uPF3Q1oGJ3

[MPM BioImpact @MPMBioImpact]

Today we’re celebrating our company @ReNAgadeTx, named to Endpoints News list of the 11 most promising biotech companies in 2023. This preclinical-stage genetic medicines company is working to untap the limitless potential of RNA medicine. https://t.co/vpzssMwMs4

[MPM BioImpact @MPMBioImpact]

Our portfolio company @ReCodeTx, a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics, today announced an extension of its Series B financing.

Read the press release here: https://t.co/p6bsmKVJDF

[MPM BioImpact @MPMBioImpact]

Join MPM BioImpact Partner Brian Goodman at the LSX World Congress in Boston Sept. 13, where he'll share his perspectives on the outlook for venture investors and investing in the science of tomorrow. For more information and to register, visit https://t.co/4WjynXMu7A

[MPM BioImpact @MPMBioImpact]

Big news in #biotech: MPM BioImpact-founded @ReNAgadeTX launches with $300M Series A financing, co-led by our team and F2 Ventures, to untap the potential of RNA to rewrite the underlying basis of disease.

[FORTUNE @FortuneMagazine]

ReNAgade Therapeutics and other early stage startups are raking in cash as science is moving at a pace that’s “unprecedented.” https://t.co/tg4fyJHb9Q

[Boston Cambridge Biotech Networks @BCBionetwork]

BCBN Feed: RNA startup launches with $300M, Merck partnership: ReNAgade Therapeutics is emerging from stealth with a leadership team hailing from Alnylam Pharmaceuticals and Moderna. The company has about ... #boston #biotech https://t.co/iKPqEyVagv

[MPM BioImpact @MPMBioImpact]

Hats off to the team at MPM BioImpact-founded @ReNAgadeTx: Integrated, multimodal, all-RNA platform to deliver, code, edit and insert genetic information to correct disease #biotech

[John Carroll @JohnCendpts]

“RNA can do this and RNA can do that. Right, but you have to get there. If you can’t get there you can’t do anything." Updated ReNAgade
https://t.co/PoRFp1Pxdj

[MPM BioImpact @MPMBioImpact]

Congratulations to our portfolio co @ReNAgadeTx: $300M+ Series A financing to dramatically transcend boundaries of RNA medicine. Financing led by MPM BioImpact & F2 Ventures. ReNAgade JV with MPM BioImpact-founded @Ornatx provides early validation of its technologies. #biotech

[ReNAgade Therapeutics @ReNAgadeTx]

We are thrilled to announce the launch of ReNAgade Therapeutics with $300M+ in Series A financing. With our comprehensive deliver, code, edit, insert technologies, we’re unlocking the limitless potential for RNA medicines. https://t.co/PKUVGQoyEb

[MPM BioImpact @MPMBioImpact]

MPM-BioImpact Principal @devinquinlan, PhD, joined Biomarker’s @dylanvneel alongside 22 other rising VCs for a Q&A on #biotech investing and creation. Read about lessons learned in #biotech #venturecapital and advice for first-time entrepreneurs. LINK: https://t.co/cAmjocsh5d

[MPM BioImpact @MPMBioImpact]

Congratulations to our friends and colleagues at MPM portfolio company Entrada Therapeutics on the new partnership with Vertex Pharmaceuticals, bringing $250M of capital to Entrada’s DM1 program and novel EEV approach to intracellular therapeutics.

[Entrada Therapeutics @entradatx]

We are proud to announce our collaboration with @VertexPharma to discover and develop Endosomal Escape Vehicle (EEVTM)-therapeutics for the potential treatment of myotonic dystrophy type 1, including our late-stage preclinical program ENTR-701. Read more: https://t.co/UppGIcNQdf.

[MPM BioImpact @MPMBioImpact]

@orna_tx, a company we and our affiliate @BioImpactCap created, was today named to @endpts list of most promising biotech companies in 2022. Congratulations to our colleague Tom Barnes and the Orna team.

[MPM BioImpact @MPMBioImpact]

MPM portfolio company @UmojaBiopharma named to @biospace NextGen Bio “Class of 2022” top life sciences startups to watch! Congratulations to our colleague @andyscharenberg and the Umoja team. Read the corresponding BioSpace article below.

[Umoja Biopharma @UmojaBiopharma]

Our Co-founder & CEO, @andyscharenberg MD, spoke with @Chicat08 in this @biospace article about Umoja’s #unified approach to overcoming limitations of current #CellTherapies. Read the article here: https://t.co/ubfk08OxNy

Read more about our science here: https://t.co/NoOFxnY3lI

[MPM BioImpact @MPMBioImpact]

MPM and @BioImpactCap, an MPM affiliate, created #AktisOncology in 2020 to develop a best-in-class, targeted alpha particle radiotherapy platform for treating solid tumors. We are excited for this important next step!

[BioSpace @biospace]

Aktis Oncology announced Thursday the completion of an $84 million Series A extension financing round to bring its class of targeted radiopharmaceuticals to a large patient pool with a broad range of solid tumors.
#AktisOncology #Biotech #BioSpace
https://t.co/eRioi13hOk